Navigation Links
Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals
Date:7/23/2014

Cambridge, MA (PRWEB) July 23, 2014

Astra Nova Training, a global provider of innovative and comprehensive consultancy and pharma training services, and the Alliance for Clinical Research Excellence and Safety (ACRES), a non-profit integrating the expertise and investments of research stakeholders worldwide to build and maintain a global system for clinical trials, are pleased to announce a strategic alliance collaboration to improve the expertise of industry professionals through improved and easily available training quality, thus enhancing greater patient safety.

Since its establishment in 2008, UK-based Astra Nova has introduced an international network of over 140 industry experts based in over 50 countries around the globe. In addition, the company has launched over 20 free and commercial online training courses, accessible on their Learning Management System. More than 5,000 professionals worldwide have obtained industry certification through their in-house and online training solutions.

ACRES, a non-profit organization operating in the public interest, is dedicated to enhancing quality, safety, integrity, and operational effectiveness in drug development and health research through the building of a global system for clinical research. To achieve this, ACRES has adopted an Alliance-based model whereby those organizations with a stake in clinical trials being conducted according to the highest standards of safety, quality, and efficiency, are the very organizations that—together—build the comprehensive, integrated system to make such excellence possible.

Astra Nova, with its strong commitment to corporate social responsibility (CSR), will make available interactive and easy-to access online training solutions for ACRES Global Platform of services. This CSR commitment, mirrored by ACRES, is exemplified in Astra Nova’s Better Industry Initiative (Bii), which provides free and commercial high-quality training courses and other resources, with an ultimate goal of better serving patients by equipping future and current industry professionals with more refined skills and workflow efficiency tools.

With Astra Nova, ACRES will provide timely information on critical training topics and materials needed globally, and they will partner on Learning Management Systems development. Other collaborative efforts involve jointly organizing multi-stakeholder events dedicated to improving the conduct of clinical research globally.

Astra Nova’s Business Development Director, Ms. Maya Zlatanova, said: “Our main goal is to improve patient safety and allow easier access to industry regulations, standards, and knowledge. We believe that everyone will benefit from this partnership, and the results of this collaboration will become visible in the very first days of establishing it.”

Dr Matthew Whalen, COO of ACRES, noted, “ACRES work is conducted through alliances, and Astra Nova brings added depth to ACRES network of organizations committed to transforming the world of clinical research.” Whalen added, “We are looking forward to working together with Astra Nova in a variety of ways to realize our shared collaboration goal of providing more innovative solutions, broader standardization, better quality of service, greater safety, and increased efficiency.”

ASTRA NOVA LTD:

More information on Astra Nova’s work can be found here. For more information, please contact Ms. Maya Zlatanova at maya(at)astranovatraining(dot)co(dot)uk.

ACRES:

More information on the Alliance for Clinical Research Excellence and Safety (ACRES) may be found here. For more information, please contact Dr. Mary F. Tobin at mtobin(at)acresglobal(dot)net.

Read the full story at http://www.prweb.com/releases/ACRES_AstraNova_Research/GregKoskiMayaZlatanove/prweb12035287.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Genedata Announces Collaboration With AstraZeneca on the Analysis of Compound Combination Experiments
2. New Drug Applications, FDA Approvals, Approved Acquisitions, Divestitures and Licensing Agreements - Research Report on Merck, Allergan, Mylan, AstraZeneca, and GlaxoSmithKline
3. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
4. Todays Technical View: AstraZeneca, GlaxoSmithKline, Keryx Biopharma, and Raptor Pharma
5. Top Five Global Cardiovascular Drug Companies 2013 Report Features Players such as Pfizer and AstraZeneca
6. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
7. Isis Pharmaceuticals Earns $10 Million Milestone Payment from AstraZeneca for ISIS-AR Rx to Treat Prostate Cancer
8. Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter of Metastatic Castrate-Resistant Prostate Cancer Patients Who Have Failed to Respond to Prior Docetaxel Treatment
9. Delta Point Strengthens Management and Expands Consultancy Services with Addition of Former AstraZeneca Executive Michael Hickey
10. UroToday Launches New Prostate Cancer Focused Content Including Immunotherapy for Metastatic Castration-resistant Patients
11. AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Research and Markets has announced the ... to their offering. ... The Global Market for Bioproducts Should Reach ... a CAGR of 8.9%, This research report ... seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and ...
(Date:3/23/2017)... Colo. , March 23, 2017  GlobeImmune, Inc. ... agreement for the sale of 12,835,490 shares of its ... NantWorks  ecosystem of companies. In connection with the sale of ... $100,000 in cash and issue to GlobeImmune 200,000 shares, ... stock. "We are pleased to enter ...
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
(Date:3/23/2017)... Colo. , March 23, 2017  Agriculture technology ... Series A financing and note conversion to commercialize its ... Planet is focused on developing products that are simultaneously ... $30 million in the last 18 months. This latest ... North Bridge Venture Partners. The company,s ...
Breaking Biology Technology:
(Date:3/22/2017)... Vigilant Solutions , a vehicle location ... announced today the appointment of retired FBI special agent ... business development. Mr. Sheridan brings more than ... focus on the aviation transportation sector, to his new ... Sheridan served as the Aviation Liaison Agent Coordinator (ALAC) ...
(Date:3/13/2017)... Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or against ... (PRNewsFoto/Dermalog Identification Systems) ... Matching" is the fastest software for biometric Face Matching on the market. The ...
(Date:3/7/2017)... March 7, 2017   HireVue , the leading ... companies identify the best talent, faster, today announced the ... Officer (CSO) and Diana Kucer as Chief ... seasoned executive team poised to drive continued growth in ... a year of record bookings in 2017. ...
Breaking Biology News(10 mins):